Agile Therapeutics, Inc. President and CEO Appointed to Board of BioNJ
Published: Feb 14, 2013
PRINCETON, NJ--(Marketwire - February 13, 2013) -
Mr. Altomari said, "I am honored to have been selected to join the board of BioNJ, which has been an instrumental player in making New Jersey a leader in the biopharmaceuticals industry through public policy initiatives, fostering leadership through networking events, and being a resource for its members."
Additionally, Mr. Altomari and Katie MacFarlane, Pharm.D., who is responsible for overseeing Agile's commercial activities, recently presented at the Pharma Market Research Conference, which took place February 5-6, 2013, in Woodcliff Lake, New Jersey. Their presentation focused on the role that market research can play in biotech companies' efforts to secure funding.
Mr. Altomari will also be making a company presentation about Agile Therapeutics at the Leerink Swann 2013 Global Healthcare Conference, taking place February 13-14, 2013, in New York.
Agile is developing a once-weekly contraceptive patch, AG200-15, designed to deliver a low daily dose of hormones, as well as a pipeline of other women's health products.
AG200-15 is an investigational combination hormonal contraceptive patch, designed to deliver a low dose of ethinyl estradiol comparable to low-dose combination oral contraceptives. The phase III trials for AG200-15 enrolled nearly 2,000 women and formed the basis for the Company's application to the US Food and Drug Administration in 2012.
The AG200-15 patch is intended to be applied once weekly for three weeks, followed by a fourth, patch-free week. The patch is designed using a soft, flexible cloth, with a silky feel, and is intended to provide excellent adhesion, comfort, and appearance.
About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and potentially more convenient methods of hormonal contraception. The Company's lead investigational product, AG200-15, is designed to be a once-weekly contraceptive patch that has recently been submitted to the FDA as a New Drug Application (NDA) for review. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that has been designed to allow stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.
Founded in 1994, BioNJ has been hard at work in its mission to enhance the climate for biotechnology in the state. As the representative of an industry that has the potential to change the course of human health, make our environment cleaner and the foods we eat safer and healthier, BioNJ is single-minded in its commitment to the growth and prosperity of this industry within the state of New Jersey. For more information, please visit: http://www.bionj.org/.
About the Pharma Market Research Conference
The Pharma Market Research Conference is the premier gathering of senior level pharmaceutical, biotechnology, medical device, and diagnostics executives in market research. The Pharma Market Research Conference is widely attended by a large variety of professionals from large, medium-sized, and emerging pharmaceutical, biotechnology, medical device, and diagnostics companies. The conference would also be of interest to market research agencies, consulting organizations, technology/software solutions, and other service providers working in this area. For more information, please visit http://pharmamarketresearchconference.com/usa.html.
About the Leerink Swann Global Healthcare Conference
The Leerink Swann Global Healthcare Conference highlights emerging themes and controversies in healthcare. Our equity analysts present surveys and moderate discussions with MEDACorp Key Opinion Leaders and industry specialists, providing unique and very timely insights. These are interspersed with senior management fireside chats and presentations by many of the most promising healthcare and life sciences companies. The Leerink Swann Global Healthcare Conference provides an opportunity for close interaction and relationship-building between healthcare companies, institutional investors, venture capitalists, hedge funds, and Leerink Swann team members.
This focused format of key stakeholders and MEDACorp specialists provides an ideal forum for interaction between investors and emerging-growth companies and distinguishes Leerink Swann events from other Wall Street conferences. For more information, please visit http://www.leerink.com/about-leerink/news--events/current-conferences.aspx.
Chantal Beaudry/Karen Famighetti for Agile Therapeutics